MarketFest, The Respiratory license/patent relationship with Univ of Alberta is still in place, and Cortex still has the composition of matter patents for the new families of low and high impacts, which includes CX-1739, CX-1942, etc.
The original license with Univ of Calif was terminated back in April 2013, but I think most of those patents had either expired, or would expire long before any Ampakine could conceivably reach the market. In the SEC filing Cortex said -
>>> In addition, as a part of assessing its strategic needs, the Company had discussed terminating its license agreement with the Regents of the University of California. The Company does not believe this license agreement is material or necessary for its drug development plan. The license fees owed by the Company under the agreement were not paid and the license was terminated by the University on April 15, 2013. <<<
News 
Market Data 
Discover 
AI
